| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scleroderma, Systemic | 70 | 2023 | 446 | 14.230 |
Why?
|
| Pulmonary Fibrosis | 39 | 2023 | 157 | 9.600 |
Why?
|
| Fibroblasts | 76 | 2023 | 902 | 7.940 |
Why?
|
| Lung | 67 | 2023 | 849 | 7.520 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 30 | 2020 | 66 | 5.590 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 12 | 2021 | 18 | 5.120 |
Why?
|
| Fibrosis | 39 | 2023 | 371 | 4.690 |
Why?
|
| Skin | 25 | 2023 | 451 | 4.300 |
Why?
|
| Extracellular Matrix | 16 | 2021 | 493 | 3.460 |
Why?
|
| Transforming Growth Factor beta | 26 | 2023 | 384 | 2.690 |
Why?
|
| Lung Diseases, Interstitial | 14 | 2023 | 110 | 2.150 |
Why?
|
| Autoantibodies | 9 | 2019 | 434 | 2.100 |
Why?
|
| Transcriptome | 8 | 2023 | 164 | 2.070 |
Why?
|
| Myofibroblasts | 13 | 2020 | 60 | 1.950 |
Why?
|
| Cells, Cultured | 48 | 2023 | 2673 | 1.920 |
Why?
|
| Bleomycin | 21 | 2020 | 67 | 1.610 |
Why?
|
| Humans | 160 | 2023 | 68618 | 1.600 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 6 | 2012 | 46 | 1.550 |
Why?
|
| Collagen | 15 | 2020 | 636 | 1.370 |
Why?
|
| Endostatins | 3 | 2015 | 11 | 1.370 |
Why?
|
| Signal Transduction | 27 | 2021 | 2689 | 1.360 |
Why?
|
| Gene Expression Regulation | 17 | 2021 | 1293 | 1.330 |
Why?
|
| Mice | 50 | 2022 | 8474 | 1.290 |
Why?
|
| Interleukin-6 | 7 | 2020 | 330 | 1.200 |
Why?
|
| Twins, Monozygotic | 5 | 2019 | 27 | 1.090 |
Why?
|
| Lung Diseases | 3 | 2022 | 175 | 1.090 |
Why?
|
| Transforming Growth Factor beta1 | 16 | 2020 | 126 | 1.080 |
Why?
|
| Animals | 63 | 2022 | 20881 | 1.050 |
Why?
|
| Estradiol | 2 | 2019 | 176 | 1.010 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2020 | 110 | 0.990 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2019 | 52 | 0.980 |
Why?
|
| Receptors, Somatostatin | 2 | 2021 | 7 | 0.970 |
Why?
|
| Protein-Lysine 6-Oxidase | 3 | 2020 | 14 | 0.950 |
Why?
|
| Mice, Inbred C57BL | 22 | 2020 | 2791 | 0.910 |
Why?
|
| Proteomics | 4 | 2021 | 246 | 0.910 |
Why?
|
| Fibronectins | 12 | 2021 | 130 | 0.880 |
Why?
|
| DNA Methylation | 4 | 2021 | 193 | 0.880 |
Why?
|
| Gene Expression Profiling | 11 | 2021 | 498 | 0.870 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2021 | 194 | 0.850 |
Why?
|
| Male | 63 | 2022 | 37321 | 0.830 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2021 | 45 | 0.820 |
Why?
|
| Adenovirus E4 Proteins | 1 | 2021 | 3 | 0.810 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2021 | 26 | 0.800 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2021 | 35 | 0.790 |
Why?
|
| MicroRNAs | 8 | 2021 | 447 | 0.770 |
Why?
|
| Intracellular Space | 2 | 2019 | 42 | 0.760 |
Why?
|
| Diseases in Twins | 2 | 2019 | 31 | 0.760 |
Why?
|
| Scleroderma, Localized | 3 | 2017 | 19 | 0.760 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2019 | 42 | 0.730 |
Why?
|
| Reactive Oxygen Species | 5 | 2019 | 499 | 0.720 |
Why?
|
| Basidiomycota | 1 | 2020 | 5 | 0.710 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 8 | 2017 | 207 | 0.710 |
Why?
|
| Early Growth Response Protein 1 | 7 | 2013 | 42 | 0.710 |
Why?
|
| Female | 59 | 2022 | 38074 | 0.700 |
Why?
|
| Cell Nucleus | 6 | 2015 | 305 | 0.690 |
Why?
|
| Mycoses | 1 | 2020 | 60 | 0.680 |
Why?
|
| DNA-Binding Proteins | 5 | 2021 | 700 | 0.670 |
Why?
|
| Scleroderma, Diffuse | 1 | 2019 | 25 | 0.660 |
Why?
|
| Cytokines | 7 | 2021 | 866 | 0.650 |
Why?
|
| Biomedical Research | 1 | 2022 | 310 | 0.650 |
Why?
|
| RNA, Long Noncoding | 4 | 2020 | 54 | 0.640 |
Why?
|
| Epigenesis, Genetic | 7 | 2021 | 163 | 0.640 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2016 | 124 | 0.640 |
Why?
|
| Physicians, Women | 1 | 2018 | 23 | 0.640 |
Why?
|
| Middle Aged | 45 | 2021 | 21147 | 0.630 |
Why?
|
| Staff Development | 1 | 2018 | 35 | 0.630 |
Why?
|
| Autoimmunity | 2 | 2011 | 118 | 0.630 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 10 | 2020 | 320 | 0.620 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 508 | 0.610 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2015 | 64 | 0.610 |
Why?
|
| Phenotype | 10 | 2020 | 947 | 0.600 |
Why?
|
| Faculty, Medical | 1 | 2018 | 110 | 0.600 |
Why?
|
| Hypertension, Pulmonary | 4 | 2017 | 232 | 0.590 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2020 | 306 | 0.590 |
Why?
|
| Leadership | 1 | 2018 | 136 | 0.570 |
Why?
|
| Phosphoproteins | 2 | 2015 | 202 | 0.570 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2020 | 214 | 0.570 |
Why?
|
| Chemokines | 2 | 2015 | 119 | 0.550 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 281 | 0.550 |
Why?
|
| Tenascin | 2 | 2016 | 39 | 0.540 |
Why?
|
| Fellowships and Scholarships | 3 | 2021 | 127 | 0.540 |
Why?
|
| RNA Polymerase III | 1 | 2015 | 7 | 0.520 |
Why?
|
| RNA, Messenger | 17 | 2017 | 1664 | 0.510 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 1173 | 0.510 |
Why?
|
| Somatomedins | 1 | 2015 | 16 | 0.510 |
Why?
|
| Gene Expression | 7 | 2017 | 770 | 0.510 |
Why?
|
| RNA-Binding Proteins | 2 | 2015 | 215 | 0.510 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2015 | 41 | 0.510 |
Why?
|
| Immunoglobulin G | 2 | 2007 | 481 | 0.490 |
Why?
|
| Blotting, Western | 13 | 2016 | 954 | 0.490 |
Why?
|
| Macrophages | 5 | 2021 | 647 | 0.470 |
Why?
|
| Biomarkers | 8 | 2021 | 1593 | 0.470 |
Why?
|
| Adult | 34 | 2021 | 21403 | 0.460 |
Why?
|
| Macrophage Activation | 1 | 2014 | 75 | 0.460 |
Why?
|
| Case-Control Studies | 12 | 2021 | 1553 | 0.440 |
Why?
|
| Caveolin 1 | 2 | 2011 | 59 | 0.430 |
Why?
|
| Peptide Fragments | 1 | 2015 | 483 | 0.430 |
Why?
|
| Purines | 1 | 2012 | 39 | 0.430 |
Why?
|
| Syndecan-2 | 1 | 2012 | 2 | 0.420 |
Why?
|
| Cell Movement | 6 | 2016 | 630 | 0.420 |
Why?
|
| Mice, Knockout | 13 | 2019 | 1692 | 0.420 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2020 | 82 | 0.420 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 2 | 2009 | 11 | 0.410 |
Why?
|
| Aged | 28 | 2021 | 14862 | 0.400 |
Why?
|
| Mice, Transgenic | 5 | 2021 | 1033 | 0.390 |
Why?
|
| Disease Models, Animal | 12 | 2019 | 2550 | 0.390 |
Why?
|
| RNA Interference | 6 | 2018 | 266 | 0.380 |
Why?
|
| Cell Adhesion Molecules | 4 | 2020 | 199 | 0.370 |
Why?
|
| Recombinant Proteins | 7 | 2019 | 742 | 0.370 |
Why?
|
| Promoter Regions, Genetic | 10 | 2021 | 615 | 0.360 |
Why?
|
| Enzyme Activation | 6 | 2015 | 791 | 0.350 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2020 | 226 | 0.340 |
Why?
|
| RNA, Small Interfering | 7 | 2019 | 434 | 0.340 |
Why?
|
| Up-Regulation | 11 | 2018 | 682 | 0.340 |
Why?
|
| MAP Kinase Signaling System | 4 | 2019 | 247 | 0.340 |
Why?
|
| Actins | 5 | 2019 | 249 | 0.330 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2009 | 82 | 0.330 |
Why?
|
| Peptides | 1 | 2012 | 455 | 0.330 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 11 | 2016 | 710 | 0.320 |
Why?
|
| Immunohistochemistry | 9 | 2019 | 1174 | 0.310 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2008 | 33 | 0.310 |
Why?
|
| Epithelial Cells | 6 | 2020 | 431 | 0.310 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2019 | 507 | 0.300 |
Why?
|
| NADPH Oxidases | 2 | 2019 | 80 | 0.300 |
Why?
|
| Connective Tissue Growth Factor | 4 | 2017 | 76 | 0.300 |
Why?
|
| Epithelium | 1 | 2007 | 172 | 0.300 |
Why?
|
| Inflammation | 5 | 2020 | 1030 | 0.290 |
Why?
|
| Antibodies, Antinuclear | 3 | 2007 | 171 | 0.290 |
Why?
|
| Antibody Formation | 1 | 2007 | 93 | 0.290 |
Why?
|
| Asthma | 2 | 2020 | 345 | 0.290 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 223 | 0.290 |
Why?
|
| Chromatography, Liquid | 2 | 2020 | 120 | 0.280 |
Why?
|
| Disease Progression | 5 | 2020 | 1038 | 0.280 |
Why?
|
| Cell Differentiation | 11 | 2021 | 1034 | 0.280 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2020 | 139 | 0.270 |
Why?
|
| Interleukin-1beta | 5 | 2018 | 88 | 0.270 |
Why?
|
| Transcription, Genetic | 7 | 2013 | 562 | 0.270 |
Why?
|
| Dinoprostone | 4 | 2017 | 110 | 0.270 |
Why?
|
| Collagen Type I | 5 | 2017 | 175 | 0.270 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2020 | 144 | 0.270 |
Why?
|
| Chemokine CCL2 | 3 | 2018 | 101 | 0.270 |
Why?
|
| Cell Line | 10 | 2020 | 1752 | 0.270 |
Why?
|
| Interferon-gamma | 3 | 2015 | 241 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2017 | 219 | 0.270 |
Why?
|
| Proof of Concept Study | 3 | 2020 | 38 | 0.260 |
Why?
|
| Transfection | 6 | 2021 | 782 | 0.260 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 1851 | 0.260 |
Why?
|
| Organ Culture Techniques | 2 | 2017 | 122 | 0.260 |
Why?
|
| STAT3 Transcription Factor | 2 | 2018 | 86 | 0.260 |
Why?
|
| Protein Binding | 8 | 2017 | 1027 | 0.260 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 2 | 2014 | 4 | 0.240 |
Why?
|
| Hyaluronan Receptors | 2 | 2017 | 142 | 0.240 |
Why?
|
| Inflammasomes | 2 | 2017 | 39 | 0.240 |
Why?
|
| CpG Islands | 3 | 2021 | 51 | 0.240 |
Why?
|
| Transcription Factors | 7 | 2016 | 753 | 0.240 |
Why?
|
| Protein Transport | 3 | 2015 | 280 | 0.240 |
Why?
|
| Cell Proliferation | 8 | 2015 | 1174 | 0.230 |
Why?
|
| Alternative Splicing | 2 | 2014 | 93 | 0.230 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2021 | 56 | 0.220 |
Why?
|
| Cathepsin L | 1 | 2023 | 10 | 0.220 |
Why?
|
| Mitochondria | 3 | 2019 | 643 | 0.220 |
Why?
|
| Cyclooxygenase 2 | 3 | 2014 | 160 | 0.220 |
Why?
|
| Histones | 4 | 2014 | 111 | 0.220 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2022 | 12 | 0.210 |
Why?
|
| Respiratory System | 1 | 2022 | 28 | 0.210 |
Why?
|
| Gene Silencing | 2 | 2014 | 137 | 0.210 |
Why?
|
| Thorax | 1 | 2022 | 49 | 0.210 |
Why?
|
| Smad2 Protein | 4 | 2017 | 42 | 0.210 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2020 | 13 | 0.210 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2014 | 216 | 0.210 |
Why?
|
| Culture Media, Conditioned | 2 | 2012 | 78 | 0.200 |
Why?
|
| Ribonucleases | 4 | 2006 | 25 | 0.200 |
Why?
|
| Aging | 2 | 2019 | 911 | 0.200 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 179 | 0.200 |
Why?
|
| Transcription Factor AP-2 | 1 | 2021 | 9 | 0.200 |
Why?
|
| T-Box Domain Proteins | 1 | 2021 | 29 | 0.200 |
Why?
|
| Chemokine CXCL10 | 2 | 2013 | 21 | 0.200 |
Why?
|
| Oxidative Stress | 4 | 2019 | 718 | 0.200 |
Why?
|
| Phosphorylation | 6 | 2018 | 1200 | 0.200 |
Why?
|
| T-Lymphocytes | 4 | 2020 | 597 | 0.190 |
Why?
|
| Primary Cell Culture | 3 | 2018 | 56 | 0.190 |
Why?
|
| Pulmonary Medicine | 1 | 2021 | 31 | 0.190 |
Why?
|
| Editorial Policies | 1 | 2021 | 32 | 0.190 |
Why?
|
| Calcium Signaling | 1 | 2021 | 97 | 0.190 |
Why?
|
| DNA, Mitochondrial | 2 | 2019 | 84 | 0.190 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 1 | 0.190 |
Why?
|
| Alleles | 4 | 2011 | 386 | 0.190 |
Why?
|
| Airway Remodeling | 1 | 2020 | 7 | 0.190 |
Why?
|
| Gene Regulatory Networks | 2 | 2019 | 94 | 0.190 |
Why?
|
| Smoke | 2 | 2014 | 46 | 0.190 |
Why?
|
| CD27 Ligand | 1 | 2020 | 1 | 0.180 |
Why?
|
| NIH 3T3 Cells | 4 | 2014 | 65 | 0.180 |
Why?
|
| Smoking | 6 | 2008 | 1452 | 0.180 |
Why?
|
| Matrix Metalloproteinases | 2 | 2019 | 223 | 0.180 |
Why?
|
| Monocytes | 1 | 2021 | 210 | 0.180 |
Why?
|
| Homeostasis | 2 | 2020 | 291 | 0.180 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2020 | 14 | 0.180 |
Why?
|
| Receptors, Notch | 1 | 2020 | 15 | 0.180 |
Why?
|
| Hydroxylation | 1 | 2020 | 41 | 0.180 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2020 | 24 | 0.180 |
Why?
|
| Folate Receptor 2 | 1 | 2019 | 2 | 0.180 |
Why?
|
| Autophagy | 3 | 2015 | 208 | 0.180 |
Why?
|
| Fluorine Radioisotopes | 1 | 2019 | 13 | 0.180 |
Why?
|
| Proline | 1 | 2020 | 52 | 0.180 |
Why?
|
| Tissue Array Analysis | 1 | 2020 | 53 | 0.180 |
Why?
|
| Toll-Like Receptors | 1 | 2020 | 56 | 0.170 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2019 | 42 | 0.170 |
Why?
|
| Autocrine Communication | 2 | 2017 | 37 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 38 | 0.170 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2019 | 59 | 0.170 |
Why?
|
| HSP72 Heat-Shock Proteins | 1 | 2019 | 1 | 0.170 |
Why?
|
| Receptor, Insulin | 1 | 2019 | 71 | 0.170 |
Why?
|
| Smad3 Protein | 5 | 2020 | 33 | 0.170 |
Why?
|
| Nerve Tissue Proteins | 2 | 2016 | 290 | 0.170 |
Why?
|
| Area Under Curve | 1 | 2020 | 238 | 0.170 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2013 | 63 | 0.170 |
Why?
|
| Phospholipase D | 1 | 2019 | 13 | 0.170 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 114 | 0.170 |
Why?
|
| Folic Acid | 1 | 2019 | 123 | 0.160 |
Why?
|
| Exosomes | 1 | 2019 | 44 | 0.160 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2018 | 15 | 0.160 |
Why?
|
| United States | 3 | 2022 | 7367 | 0.160 |
Why?
|
| Genetic Markers | 1 | 2019 | 144 | 0.160 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2018 | 20 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2009 | 250 | 0.160 |
Why?
|
| Lysosomes | 1 | 2019 | 136 | 0.160 |
Why?
|
| Cell Cycle | 1 | 2020 | 312 | 0.160 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 213 | 0.160 |
Why?
|
| Molecular Imaging | 1 | 2018 | 45 | 0.160 |
Why?
|
| Career Mobility | 1 | 2018 | 34 | 0.160 |
Why?
|
| Apoptosis | 5 | 2014 | 1641 | 0.160 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 40 | 0.160 |
Why?
|
| rho-Associated Kinases | 1 | 2018 | 32 | 0.160 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2018 | 137 | 0.160 |
Why?
|
| Energy Metabolism | 1 | 2020 | 222 | 0.150 |
Why?
|
| Smad7 Protein | 1 | 2018 | 11 | 0.150 |
Why?
|
| Biopsy | 6 | 2018 | 540 | 0.150 |
Why?
|
| beta Catenin | 3 | 2019 | 73 | 0.150 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2016 | 117 | 0.150 |
Why?
|
| Career Choice | 1 | 2018 | 98 | 0.150 |
Why?
|
| Models, Genetic | 1 | 2018 | 161 | 0.150 |
Why?
|
| Collagen Type VI | 2 | 2014 | 5 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 536 | 0.150 |
Why?
|
| Hydroxyproline | 2 | 2015 | 33 | 0.150 |
Why?
|
| Pericytes | 1 | 2018 | 81 | 0.150 |
Why?
|
| Sirtuin 3 | 1 | 2017 | 6 | 0.150 |
Why?
|
| Acyltransferases | 1 | 2017 | 40 | 0.150 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2017 | 26 | 0.150 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2017 | 22 | 0.150 |
Why?
|
| Transcription Factor AP-1 | 2 | 2017 | 61 | 0.150 |
Why?
|
| Program Development | 1 | 2018 | 240 | 0.140 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2020 | 146 | 0.140 |
Why?
|
| Immunoprecipitation | 2 | 2009 | 132 | 0.140 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2016 | 282 | 0.140 |
Why?
|
| Liver X Receptors | 1 | 2016 | 8 | 0.140 |
Why?
|
| Lymphocytes | 2 | 2020 | 228 | 0.140 |
Why?
|
| Synaptotagmins | 1 | 2016 | 3 | 0.140 |
Why?
|
| Receptors, Virus | 1 | 2016 | 20 | 0.140 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2014 | 33 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2018 | 502 | 0.140 |
Why?
|
| Gelatinases | 1 | 2015 | 12 | 0.130 |
Why?
|
| Lung Injury | 1 | 2016 | 38 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 1046 | 0.130 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2016 | 114 | 0.130 |
Why?
|
| Nerve Growth Factors | 1 | 2016 | 75 | 0.130 |
Why?
|
| Drug Discovery | 1 | 2017 | 94 | 0.130 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2017 | 117 | 0.130 |
Why?
|
| Aldehyde-Lyases | 1 | 2015 | 2 | 0.130 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 50 | 0.130 |
Why?
|
| Receptors, Lipoxin | 1 | 2015 | 3 | 0.130 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2015 | 4 | 0.130 |
Why?
|
| Lipoxins | 1 | 2015 | 4 | 0.130 |
Why?
|
| Trans-Activators | 3 | 2014 | 237 | 0.130 |
Why?
|
| Bronchi | 2 | 2013 | 59 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2015 | 25 | 0.130 |
Why?
|
| Receptors, Cytokine | 1 | 2015 | 19 | 0.130 |
Why?
|
| Endothelial Cells | 2 | 2016 | 384 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 248 | 0.130 |
Why?
|
| Interferon-alpha | 1 | 2015 | 46 | 0.130 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 101 | 0.130 |
Why?
|
| Smad4 Protein | 1 | 2014 | 10 | 0.120 |
Why?
|
| Interleukin-17 | 1 | 2015 | 62 | 0.120 |
Why?
|
| Wnt Proteins | 2 | 2019 | 57 | 0.120 |
Why?
|
| Interleukin-12 | 1 | 2015 | 75 | 0.120 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2015 | 37 | 0.120 |
Why?
|
| Antibodies | 2 | 1995 | 241 | 0.120 |
Why?
|
| Autoantigens | 2 | 2007 | 91 | 0.120 |
Why?
|
| Quality of Life | 1 | 2023 | 1515 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2015 | 411 | 0.120 |
Why?
|
| Antigens, CD | 2 | 2012 | 230 | 0.120 |
Why?
|
| Histocompatibility Antigens | 1 | 2014 | 12 | 0.120 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2014 | 13 | 0.120 |
Why?
|
| Kidney | 1 | 2019 | 945 | 0.120 |
Why?
|
| Immunity, Innate | 3 | 2022 | 156 | 0.120 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2013 | 9 | 0.120 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2013 | 4 | 0.120 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2013 | 11 | 0.110 |
Why?
|
| Skin Physiological Phenomena | 1 | 2013 | 13 | 0.110 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2013 | 4 | 0.110 |
Why?
|
| Receptors, Calcitriol | 1 | 2014 | 49 | 0.110 |
Why?
|
| Interleukin-1 | 2 | 2004 | 86 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 33 | 0.110 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2015 | 86 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2012 | 199 | 0.110 |
Why?
|
| Mucus | 1 | 2013 | 33 | 0.110 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 48 | 0.110 |
Why?
|
| Cellular Senescence | 1 | 2014 | 112 | 0.110 |
Why?
|
| Pulmonary Emphysema | 1 | 2014 | 71 | 0.110 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 397 | 0.110 |
Why?
|
| Ligands | 3 | 2012 | 317 | 0.110 |
Why?
|
| Cell Division | 4 | 2003 | 541 | 0.110 |
Why?
|
| Estrogen Receptor Antagonists | 1 | 2013 | 1 | 0.110 |
Why?
|
| Telomere | 1 | 2013 | 59 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2013 | 266 | 0.110 |
Why?
|
| GATA6 Transcription Factor | 1 | 2013 | 27 | 0.110 |
Why?
|
| Interleukin-13 | 1 | 2013 | 16 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2015 | 193 | 0.110 |
Why?
|
| Proto-Oncogenes | 1 | 1993 | 37 | 0.110 |
Why?
|
| Semaphorins | 1 | 2012 | 7 | 0.110 |
Why?
|
| Myocardium | 1 | 2019 | 1204 | 0.110 |
Why?
|
| HLA-DR Antigens | 2 | 2011 | 41 | 0.110 |
Why?
|
| Genes, X-Linked | 1 | 2012 | 6 | 0.110 |
Why?
|
| Telomerase | 1 | 2013 | 85 | 0.110 |
Why?
|
| DNA | 2 | 2006 | 597 | 0.110 |
Why?
|
| Hexosaminidases | 1 | 2012 | 7 | 0.110 |
Why?
|
| Chromosomes, Human, X | 1 | 2012 | 24 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2017 | 626 | 0.100 |
Why?
|
| Cicatrix | 1 | 2013 | 60 | 0.100 |
Why?
|
| Nuclear Proteins | 3 | 2016 | 271 | 0.100 |
Why?
|
| Repressor Proteins | 2 | 2011 | 183 | 0.100 |
Why?
|
| Adjuvants, Immunologic | 1 | 2012 | 63 | 0.100 |
Why?
|
| Down-Regulation | 4 | 2017 | 447 | 0.100 |
Why?
|
| Antibody Specificity | 2 | 2009 | 98 | 0.100 |
Why?
|
| Blood Proteins | 1 | 1992 | 94 | 0.100 |
Why?
|
| Interleukin-4 | 1 | 1992 | 69 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2013 | 282 | 0.100 |
Why?
|
| Gene Products, gag | 1 | 1991 | 11 | 0.100 |
Why?
|
| Caspase 1 | 1 | 2011 | 22 | 0.100 |
Why?
|
| Retroviridae | 1 | 1991 | 29 | 0.100 |
Why?
|
| Acetylation | 4 | 2014 | 94 | 0.100 |
Why?
|
| Early Growth Response Protein 2 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Early Growth Response Transcription Factors | 1 | 2011 | 1 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2018 | 7277 | 0.100 |
Why?
|
| Cell Extracts | 1 | 2011 | 21 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2015 | 617 | 0.100 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 134 | 0.100 |
Why?
|
| Cell Compartmentation | 1 | 2011 | 41 | 0.100 |
Why?
|
| Interleukin-8 | 3 | 2018 | 71 | 0.100 |
Why?
|
| Subcellular Fractions | 1 | 2011 | 92 | 0.090 |
Why?
|
| In Vitro Techniques | 1 | 2012 | 765 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 371 | 0.090 |
Why?
|
| NF-kappa B | 1 | 2013 | 432 | 0.090 |
Why?
|
| Extracellular Space | 1 | 2011 | 121 | 0.090 |
Why?
|
| Cytoplasm | 1 | 2011 | 155 | 0.090 |
Why?
|
| Endocytosis | 1 | 2011 | 113 | 0.090 |
Why?
|
| Base Sequence | 4 | 2017 | 1015 | 0.090 |
Why?
|
| Chronic Disease | 4 | 2017 | 1330 | 0.090 |
Why?
|
| Models, Biological | 2 | 2020 | 981 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2800 | 0.090 |
Why?
|
| PPAR gamma | 1 | 2010 | 95 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 114 | 0.090 |
Why?
|
| Lung Transplantation | 1 | 2011 | 88 | 0.090 |
Why?
|
| Rats | 3 | 2013 | 5300 | 0.090 |
Why?
|
| Ventricular Remodeling | 1 | 2013 | 318 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 3 | 2016 | 196 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2021 | 786 | 0.090 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2009 | 12 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2016 | 209 | 0.080 |
Why?
|
| Thrombin | 2 | 2013 | 117 | 0.080 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2009 | 55 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2011 | 77 | 0.080 |
Why?
|
| Vitamin D | 1 | 2014 | 516 | 0.080 |
Why?
|
| Child | 3 | 2015 | 6405 | 0.080 |
Why?
|
| Survival Rate | 2 | 2009 | 1056 | 0.080 |
Why?
|
| Adolescent | 4 | 2015 | 8912 | 0.080 |
Why?
|
| Flow Cytometry | 3 | 2016 | 489 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2011 | 2358 | 0.080 |
Why?
|
| Pyridones | 2 | 2020 | 40 | 0.080 |
Why?
|
| Wound Healing | 3 | 2020 | 260 | 0.080 |
Why?
|
| Islets of Langerhans | 1 | 2008 | 87 | 0.080 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2008 | 63 | 0.080 |
Why?
|
| Immunologic Techniques | 1 | 2007 | 30 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 157 | 0.080 |
Why?
|
| Autoimmune Diseases | 2 | 2007 | 186 | 0.080 |
Why?
|
| B-Lymphocytes | 2 | 2007 | 329 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 627 | 0.070 |
Why?
|
| NADPH Oxidase 4 | 2 | 2017 | 17 | 0.070 |
Why?
|
| Tobacco | 1 | 2008 | 161 | 0.070 |
Why?
|
| Genomics | 2 | 2005 | 168 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 807 | 0.070 |
Why?
|
| DNA, Single-Stranded | 1 | 2007 | 41 | 0.070 |
Why?
|
| Complement C3 | 1 | 2007 | 101 | 0.070 |
Why?
|
| Integrins | 1 | 2007 | 115 | 0.070 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 103 | 0.070 |
Why?
|
| Chemotactic Factors | 1 | 2006 | 14 | 0.070 |
Why?
|
| Respiratory Mucosa | 1 | 2007 | 52 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 411 | 0.070 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2008 | 195 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2007 | 258 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2006 | 145 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2020 | 178 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 284 | 0.060 |
Why?
|
| Mesoderm | 1 | 2006 | 231 | 0.060 |
Why?
|
| Systems Biology | 1 | 2005 | 25 | 0.060 |
Why?
|
| Chemotaxis | 2 | 2016 | 38 | 0.060 |
Why?
|
| Insulin | 1 | 2008 | 619 | 0.060 |
Why?
|
| Familial Primary Pulmonary Hypertension | 2 | 2017 | 25 | 0.060 |
Why?
|
| Twin Studies as Topic | 1 | 2005 | 3 | 0.060 |
Why?
|
| Cell Count | 2 | 2016 | 248 | 0.060 |
Why?
|
| Microdissection | 1 | 2005 | 15 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2006 | 244 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 68 | 0.060 |
Why?
|
| Lasers | 1 | 2005 | 61 | 0.060 |
Why?
|
| Kinetics | 3 | 2001 | 1047 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 511 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2005 | 251 | 0.060 |
Why?
|
| Lymphotoxin-alpha | 1 | 2004 | 9 | 0.060 |
Why?
|
| Gastroesophageal Reflux | 1 | 2007 | 318 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2005 | 295 | 0.060 |
Why?
|
| Time Factors | 1 | 2012 | 4655 | 0.060 |
Why?
|
| Exons | 2 | 2014 | 122 | 0.060 |
Why?
|
| Cytosol | 2 | 2012 | 123 | 0.060 |
Why?
|
| Heart Failure | 1 | 2013 | 1180 | 0.060 |
Why?
|
| Algorithms | 2 | 2020 | 1196 | 0.060 |
Why?
|
| Twins, Dizygotic | 1 | 2003 | 25 | 0.060 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2004 | 144 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 2004 | 270 | 0.060 |
Why?
|
| Histocompatibility Testing | 1 | 2003 | 38 | 0.060 |
Why?
|
| Hydrogen Peroxide | 2 | 2017 | 168 | 0.050 |
Why?
|
| DNA Primers | 2 | 2013 | 302 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 301 | 0.050 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 337 | 0.050 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2022 | 13 | 0.050 |
Why?
|
| Benzamides | 2 | 2013 | 156 | 0.050 |
Why?
|
| Epitopes | 1 | 2022 | 146 | 0.050 |
Why?
|
| Dermis | 1 | 2001 | 29 | 0.050 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2001 | 13 | 0.050 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2021 | 23 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 2077 | 0.050 |
Why?
|
| Vaccination | 1 | 2022 | 189 | 0.050 |
Why?
|
| Gene Ontology | 1 | 2021 | 31 | 0.050 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2020 | 8 | 0.050 |
Why?
|
| Macrophages, Alveolar | 1 | 2020 | 34 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2022 | 215 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2003 | 1447 | 0.050 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 37 | 0.050 |
Why?
|
| Histone Code | 1 | 2020 | 5 | 0.040 |
Why?
|
| Histone Acetyltransferases | 2 | 2010 | 13 | 0.040 |
Why?
|
| Young Adult | 3 | 2018 | 5717 | 0.040 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2020 | 59 | 0.040 |
Why?
|
| Mucolipidoses | 1 | 2019 | 2 | 0.040 |
Why?
|
| Methods | 1 | 1999 | 156 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 319 | 0.040 |
Why?
|
| Dependovirus | 1 | 2019 | 34 | 0.040 |
Why?
|
| Clone Cells | 1 | 1999 | 67 | 0.040 |
Why?
|
| Piperidines | 1 | 2020 | 123 | 0.040 |
Why?
|
| Exocytosis | 1 | 2019 | 34 | 0.040 |
Why?
|
| Computational Biology | 1 | 2021 | 190 | 0.040 |
Why?
|
| Indoles | 1 | 2020 | 146 | 0.040 |
Why?
|
| Radioactive Tracers | 1 | 2018 | 5 | 0.040 |
Why?
|
| Incidence | 1 | 2003 | 1603 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2014 | 492 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2020 | 201 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 307 | 0.040 |
Why?
|
| Histone Deacetylases | 2 | 2010 | 99 | 0.040 |
Why?
|
| Oncostatin M | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cell Cycle Proteins | 2 | 2014 | 230 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 2019 | 173 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 55 | 0.040 |
Why?
|
| DNA Damage | 1 | 2019 | 190 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2011 | 207 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1140 | 0.040 |
Why?
|
| Pyrazolones | 1 | 2017 | 2 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2004 | 756 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 2013 | 226 | 0.040 |
Why?
|
| 3' Untranslated Regions | 1 | 2017 | 56 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2019 | 291 | 0.040 |
Why?
|
| Superoxides | 1 | 2017 | 70 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2017 | 18 | 0.040 |
Why?
|
| Liver | 1 | 2022 | 1118 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 349 | 0.040 |
Why?
|
| Stilbenes | 1 | 2017 | 57 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2017 | 149 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 652 | 0.030 |
Why?
|
| Netrin-1 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 103 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2016 | 41 | 0.030 |
Why?
|
| Solubility | 1 | 2016 | 134 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 46 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2017 | 190 | 0.030 |
Why?
|
| Twist-Related Protein 1 | 1 | 2016 | 13 | 0.030 |
Why?
|
| Collagen Type III | 1 | 2016 | 21 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2016 | 31 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2016 | 236 | 0.030 |
Why?
|
| Immediate-Early Proteins | 2 | 2007 | 63 | 0.030 |
Why?
|
| Endopeptidases | 1 | 2015 | 52 | 0.030 |
Why?
|
| Vanadates | 1 | 1995 | 12 | 0.030 |
Why?
|
| Heterozygote | 1 | 2016 | 174 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1864 | 0.030 |
Why?
|
| Leukemia, Myeloid | 1 | 1995 | 39 | 0.030 |
Why?
|
| Cell-Free System | 1 | 1995 | 43 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2015 | 25 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 1995 | 41 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 37 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1995 | 56 | 0.030 |
Why?
|
| Endoplasmic Reticulum, Rough | 1 | 2015 | 3 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 658 | 0.030 |
Why?
|
| Pyridines | 1 | 2017 | 261 | 0.030 |
Why?
|
| Proteolysis | 1 | 2015 | 97 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 737 | 0.030 |
Why?
|
| Serpin E2 | 1 | 2014 | 8 | 0.030 |
Why?
|
| Culture Media, Serum-Free | 1 | 2015 | 35 | 0.030 |
Why?
|
| Acute Disease | 1 | 1997 | 658 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2016 | 111 | 0.030 |
Why?
|
| Potassium Channel Blockers | 1 | 2014 | 32 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 368 | 0.030 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2014 | 27 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2015 | 235 | 0.030 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2015 | 61 | 0.030 |
Why?
|
| Tyrosine | 1 | 1995 | 196 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2014 | 58 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 135 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 183 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 2017 | 419 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 138 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2014 | 32 | 0.030 |
Why?
|
| beta-Galactosidase | 1 | 2014 | 88 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 34 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 622 | 0.030 |
Why?
|
| Echocardiography | 1 | 2017 | 515 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 1995 | 314 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 52 | 0.030 |
Why?
|
| Cyclooxygenase 1 | 1 | 2014 | 29 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 455 | 0.030 |
Why?
|
| Cell Survival | 2 | 2009 | 901 | 0.030 |
Why?
|
| Receptors, CXCR5 | 1 | 2013 | 4 | 0.030 |
Why?
|
| CREST Syndrome | 1 | 2013 | 5 | 0.030 |
Why?
|
| Mucin 5AC | 1 | 2013 | 3 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2013 | 26 | 0.030 |
Why?
|
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2013 | 2 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1995 | 852 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2013 | 10 | 0.030 |
Why?
|
| Fetus | 1 | 2014 | 157 | 0.030 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2013 | 6 | 0.030 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2013 | 29 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 272 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2013 | 77 | 0.030 |
Why?
|
| Culture Media | 1 | 2013 | 155 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2013 | 26 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 219 | 0.030 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2013 | 7 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2013 | 204 | 0.030 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2013 | 21 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2013 | 93 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 73 | 0.030 |
Why?
|
| Demography | 1 | 2014 | 279 | 0.030 |
Why?
|
| Molecular Probe Techniques | 1 | 1993 | 7 | 0.030 |
Why?
|
| Receptors, GABA-A | 1 | 2013 | 89 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 2013 | 47 | 0.030 |
Why?
|
| Electron Transport Complex III | 1 | 2012 | 5 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2013 | 223 | 0.030 |
Why?
|
| Genes, myc | 1 | 1993 | 26 | 0.030 |
Why?
|
| Immunoassay | 1 | 2013 | 64 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 58 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 240 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2012 | 134 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2013 | 324 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 166 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 1992 | 164 | 0.030 |
Why?
|
| Procollagen | 1 | 1992 | 31 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2012 | 188 | 0.030 |
Why?
|
| Piperazines | 1 | 2013 | 206 | 0.030 |
Why?
|
| Pneumonia | 1 | 2013 | 110 | 0.030 |
Why?
|
| Hypoxia | 1 | 2013 | 169 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2012 | 144 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2013 | 189 | 0.030 |
Why?
|
| Cross Reactions | 1 | 1991 | 57 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2011 | 3 | 0.020 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2011 | 3 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 170 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1040 | 0.020 |
Why?
|
| HLA-DRB1 Chains | 1 | 2011 | 21 | 0.020 |
Why?
|
| Software | 1 | 2014 | 418 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 1995 | 375 | 0.020 |
Why?
|
| Connective Tissue | 1 | 2011 | 61 | 0.020 |
Why?
|
| Risk Factors | 2 | 2014 | 5731 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2011 | 90 | 0.020 |
Why?
|
| Adipogenesis | 1 | 2010 | 17 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 4848 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 92 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 71 | 0.020 |
Why?
|
| South Carolina | 1 | 2017 | 2752 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2010 | 351 | 0.020 |
Why?
|
| Methylation | 1 | 2010 | 56 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2010 | 27 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1995 | 629 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 929 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2010 | 396 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 1213 | 0.020 |
Why?
|
| Integrin alpha5 | 1 | 2009 | 2 | 0.020 |
Why?
|
| Wnt-5a Protein | 1 | 2009 | 5 | 0.020 |
Why?
|
| Luciferases | 1 | 2009 | 105 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 116 | 0.020 |
Why?
|
| RNA Stability | 1 | 2009 | 55 | 0.020 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2008 | 14 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2008 | 150 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2008 | 145 | 0.020 |
Why?
|
| Binding Sites | 2 | 2003 | 631 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2008 | 94 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 233 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 2083 | 0.020 |
Why?
|
| Pancreas | 1 | 2008 | 225 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 2007 | 62 | 0.020 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2007 | 20 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2007 | 132 | 0.020 |
Why?
|
| Texas | 1 | 2007 | 92 | 0.020 |
Why?
|
| Ions | 1 | 2007 | 50 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2006 | 17 | 0.020 |
Why?
|
| Microscopic Angioscopy | 1 | 2006 | 1 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2007 | 49 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2007 | 147 | 0.020 |
Why?
|
| Cell Nucleolus | 1 | 2006 | 14 | 0.020 |
Why?
|
| Colorado | 1 | 2006 | 26 | 0.020 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2006 | 44 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 189 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2006 | 95 | 0.020 |
Why?
|
| Cell Communication | 1 | 2007 | 116 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2006 | 140 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2006 | 57 | 0.020 |
Why?
|
| Prevalence | 1 | 2011 | 1619 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2007 | 208 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 532 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 579 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1070 | 0.020 |
Why?
|
| Cilia | 1 | 2007 | 94 | 0.020 |
Why?
|
| HIV Infections | 1 | 2013 | 791 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2008 | 631 | 0.020 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2004 | 28 | 0.020 |
Why?
|
| Protein Kinase C-alpha | 1 | 2004 | 24 | 0.020 |
Why?
|
| Receptor, PAR-1 | 1 | 2004 | 30 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2004 | 37 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2004 | 64 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2004 | 32 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 97 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 529 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 955 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2003 | 28 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1745 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 1054 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 175 | 0.010 |
Why?
|
| COS Cells | 1 | 2003 | 155 | 0.010 |
Why?
|
| Southeastern United States | 1 | 2004 | 281 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2004 | 308 | 0.010 |
Why?
|
| Protein Precursors | 1 | 2003 | 105 | 0.010 |
Why?
|
| Logistic Models | 1 | 2007 | 1420 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 322 | 0.010 |
Why?
|
| Comorbidity | 1 | 2007 | 1426 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 370 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 786 | 0.010 |
Why?
|
| Prognosis | 1 | 2007 | 2093 | 0.010 |
Why?
|
| DNA Fingerprinting | 1 | 2001 | 11 | 0.010 |
Why?
|
| HLA-DQ Antigens | 1 | 2001 | 19 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 1083 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 2001 | 75 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2007 | 3705 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 1995 | 35 | 0.010 |
Why?
|